3 hours Kyverna Therapeutics (NASDAQ:KYTX) Coverage Initiated at Rodman & Renshaw MarketBeat
Rodman & Renshaw initiated coverage on shares of Kyverna Therapeutics in a research note on Wednesday. They set a “buy” rating and a $16.00 price objective for the company.